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Goal: Cerebral amyloid angiopathy (CAA) is a frequent cause of atypical intracerebral
hemorrhage (ICH) in the elderly. Stroke risk factors such as arterial hypertension (AHT),
atrial fibrillation (AFib), diabetes mellitus (DM), and renal dysfunction (RD) are increasingly
apparent in these patients. In this retrospective study, we analyzed the presence of these
stroke risk factors in different initial CAA presentations comprising cerebral microbleeds
(CMB), acute ischemic stroke (AIS), cortical superficial hemosiderosis (cSS), or lobar ICH
(LICH) and evaluated their influence on the initial clinical presentation of patients with CAA.
Material and Methods: We identified patients with at least possible CAA defined by
the modified Boston criteria admitted to the Department of Neurology or Neurosurgery
from 2002 to 2018.
Findings: In the overall cohort of 209 patients, we analyzed the correlation between the
number of stroke risk factors and the initial clinical presentation of patients with CAA and
could show the high multimorbidity of the collective. There are large differences between
the subgroups with different initial clinical presentations, e.g., patients with CMB as initial
CAA presentation have the highest number of cerebrovascular risk factors and recurrent
AIS, whereas AFib is more frequent in the Neurosurgery Department.
Conclusion: There is a distinct overlap between the subgroups of CAA manifestations
and stroke risk factors that need to be verified in larger patient collectives. Since these
comorbidities are likely to influence the clinical course of CAA, they represent possible
targets for secondary prevention until specific treatment for CAA becomes available.
Keywords: cerebral amyloid angiopathy, intracerebral hemorrhage, long term outcome, risk factors
(cardiovascular) comorbidities, computer tomography, magnetic resonance imaging
INTRODUCTION
Cerebral amyloid angiopathy (CAA) is a type 2 small vessel disease (SVD) and is responsible for up
to 20% of non-traumatic intracerebral hemorrhages (ICH). It is surpassed only by type 1 SVD with
its driving risk factors arterial hypertension (AHT) and diabetes mellitus (DM) (1–5). Currently,
the only established genetic risk factors for CAA are apolipoprotein E ε2 and ε4 (1, 2, 4, 6–10).
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Since specific therapies for CAA do not exist, secondary
prevention against recurrent CAA-related ICH is required as
a strict antihypertensive management and the avoidance of
additional cerebrovascular risk factors (1, 4, 8, 11, 12). Yet, the
impact of established vascular risk factors on the development
and course of CAA is still being investigated as the overlap
with CAA increases with age. The current study aims to
characterize the presence of vascular risk factors in different
initial presentations of patients with at least possible CAA.
MATERIALS AND METHODS
The study was approved by the Ethical Review Board of the
University of Regensburg (reference: 16-101-0050/16-050-101).
The goal of the study was to address the question, whether single
risk factors and the number of risk factors will influence the initial
presentation of patients with at least possible CAA, which was
subgrouped into LICH, AIS, CMB, and cSAH/cSS.
Discharge letters of patients treated in the Department of
Neurology at the University of Regensburg or the Department
of Neurosurgery at the University Hospital Regensburg between
2002 and 2018 were screened for the diagnosis of CAA according
to the modified Boston criteria (13). According to the modified
Boston criteria, patients in the LICH-group could also be
included by cCT, if the modified Boston criteria were fulfilled.
Patients of the other three groups were included on basis of cMRI
(Figure 1).
All available magnetic resonance imaging (MRI) data prior,
during, or upon follow-up of the initial hospital stay were
examined by trained study authors (AW and JK) who were
blinded for the risk factors, and discussed where necessary
with the neuroradiologic department for CMB using the MARS
criteria (The Microbleed Anatomical Rating Scale criteria) and
for cSAH/cSS, for correct classification of the patients into the
subgroups (14, 15). cSS was further subgrouped in focal (less
than four affected sulci) and disseminated cSS (more than four
affected sulci) (16). In addition, we searched for recent ischemic
lesions on diffusion-weighted imaging sequences, white matter
hyperintensities (WMH) classified by the Fazekas score, residual
lesions caused by previous AIS and ICH, and cerebral edema (17,
18). Classification of CAA in subtypes was performed according
to the primary manifestation of CAA in the individual patient:
patients with a (symptomatic) LICHwere grouped into the LICH
group, patients who got the diagnosis of CAA in an MRI for any
Abbreviations: ACC, common carotid artery; AFib, atrial fibrillation; AHT,
arterial hypertension; AIS, acute ischemic stroke; CAA, cerebral amyloid
angiopathy; CCA, common carotid artery; CMB, cerebral microbleeding(s); cSAH,
cortical subarachnoid hemorrhage; cSS, cortical superficial hemosiderosis; DM,
diabetes mellitus; DWL, deep white matter lesions; ECG, electrocardiogram;
GFR, glomerular filtration rate; ICA, internal carotid artery; ICH, intracerebral
hemorrhage; IDM, insulin-dependent DM; LDL, low-density lipoprotein; LICH,
lobar ICH; LVH, left ventricular hypertrophy; MARS criteria, The Microbleed
Anatomical Rating Scale criteria; MRI, magnetic resonance imaging; NASCET,
North Atlantic Carotid Artery Trial; NIDM, non-insulin-dependent DM;
PI, pulsatility index; PiB, Pittsburgh compound B; PWML, periventricular
white matter lesions; RD, renal dysfunction; RI, resistance index; SVD,
small vessel disease; TTE, transthoracic echocardiography; WMH, white
matter hyperintensities.
other reason and showed multiple strictly lobar CMB (defined
as >/= 5 CMB) were grouped into the CMB group, patients
with symptomatic or asymptomatic cSS or a cSAH after exclusion
of other reasons for cSAH were grouped into the cSS/cSAH
group and patients who presented with an AIS proven by MRI
who fulfilled diagnostic criteria for CAA were grouped into the
AIS group.
To avoid misclassification of patients with only single CMBs
as CAA, we defined a cutoff of >/=5 CMBs in accordance with
Charidimou et al. (19) and Wilson et al. (20) as necessary for
the diagnosis of CAA if other inclusion criteria like strictly lobar
major ICH or cSS were lacking.
First, the following basic data were extracted from medical
records for the index event: age and sex, symptoms at
presentation, and AHT (first documented blood pressure
at presentation, antihypertensive medication, or history of
hypertension). A systolic blood pressure > 180 mmHg or
diastolic blood pressure > 120 mmHg at first measurement
(as assessed either by paramedics or in the emergency
department) was defined as a hypertensive crisis. DM was
defined as HbA1c > 6.5% (>58 mmol/mol) or preexisting
antidiabetic medication and was subgrouped into insulin-
dependent (IDM) and non-insulin-dependent (NIDM).
Hypercholesterinemia was defined as LDL > 110 mg/dl or
previous therapy with lipid-lowering drugs like statins or
fibrates. The glomerular filtration rate (GFR), according to the
Cockroft-Gault formula and therapy with diuretics were used
to classify patients with renal insufficiency, with a GFR < 60
ml/min defined as renal failure. Cardiac comorbidities (defined
as cardiac insufficiency, coronary heart disease, and cardiac
arrhythmia) were recorded wherever possible. Furthermore,
the diagnosis of AFib was evaluated from the records of
patients, including electrocardiogram (ECG) monitoring results,
if available. In patients with more than one contact to the
Departments of Neurology or Neurosurgery, further, ICH/AIS
were recorded.
To characterize the atherosclerotic load linked to the
aforementioned vascular risk factors, we analyzed all available
neurosonographic examinations and noted the diameter of the
common carotid artery (CCA), intima-media thickness ratio,
resistance index (RI) defined as RI = (S-D)/S (S = maximal
systolic Doppler-frequency; D = maximal diastolic Doppler-
frequency), and pulsatility index (PI) defined as PI = (S-D)/M
(S = maximal systolic Doppler-frequency; D = maximal
diastolic Doppler-frequency, M = mean velocity). In patients
with unilateral stenosis of the internal carotid artery (ICA),
classification according to the North Atlantic Carotid Artery
Trial (NASCET) (21) was applied for assessment of the intima-
media thickness ratio and RI of the contralateral ICA were
used. Furthermore, the echogenicity of plaques in the common
carotid artery (CCA) was graded from 1 to 4 as echolucent,
predominantly echolucent, predominantly echogenic, or
echogenic (22). Transthoracic echocardiography (TTE) was
graded, wherever available in left ventricular hypertrophy (LVH),
wall motion abnormalities, diastolic dysfunction, valvular
sclerosis, valvular insufficiencies or stenoses, and reduced
ejection fraction.
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FIGURE 1 | Figure resuming data collection.
The percentage of risk factors for each patient subgroup was
evaluated. Therefore, each of the seven possible risk factors
[AHT, DM, atrial fibrillation (AFib), cardiac comorbidities, renal
comorbidities, hypercholesterinemia, and hyperalbuminemia] in
each patient was rated as present or absent. In the case of patients
with several parameters missing, the percentage of present risk
factors of patients with known risk factors was calculated, and
this number was compared for the four subgroups.
Statistical analysis was done using Python’s scipy.stats. For
group comparisons, either two-tailed t-test, chi-square tests on
contingency tables, or ANOVA were applied to the data as
given in the text. P < 0.05 were considered significant. Data on
subgroup analyses are available upon request.
RESULTS
Overall, we identified 209 patients with at least possible diagnosis
of CAA according to the modified Boston criteria, 149 from
the Department of Neurology, and 60 from the Department of
Neurosurgery. Definite CAA was found in 15 patients, probable
CAA with supporting pathology in 20 patients, probable CAA
in 141 patients, and possible CAA in 33 patients. In the overall
cohort, male and female patients were almost equally present
(male 50.2%/105 patients, female 49.8%/104 patients), the
average age was 72.32 years, with patients from the Department
of Neurology slightly older than patients from the Department of
Neurosurgery (73.05 vs. 70.50 years, two-sided t-test: p < 0.039),
and women slightly older than men (73.3 vs. 71.4 years, non-
significant, p > 0.094).
Due to the retrospective study design and the different
diagnostical standard operating procedures in the Department
of Neurology and Department of Neurosurgery, the information
available on comorbidities and diagnostic procedures performed
on the included patients were heterogeneous and partly
incomplete. Thus, information about hypertension was available
for 190 patients, HbA1c or diabetes for 206 patients, AFib
for 201 patients, information on cardiovascular comorbidities
in 203 patients, low-density lipoprotein (LDL) or medication
for hypercholesterolemia for 188 patients, and intake of
diuretics or GFR for diagnosis of chronic kidney disease in
190 cases.
All known cardiovascular comorbidities were registered on
the admission of the patient as part of the anamnesis regardless
of whether or not they were related to the acute symptomatic.
These were in detail: coronary heart disease including those after
coronary artery bypass graft or stent deployment, myocardial
infarction, cardiac arrhythmia, heart failure, cardiac valve
implantation, peripheral arterial occlusive disease including
those after stent or bypass surgery, gastrointestinal ischemia, any
stenosis or occlusion of brain supplying arteries including post
carotid endarterectomy and stenting, ischemic or hemorrhagic
stroke or transient ischemic attack, and renal insufficiency. Due
to the retrospective study design only few patients had sufficient
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FIGURE 2 | The primary manifestation of cerebral amyloid angiopathy (CAA) in
men vs. women such as lobar ICH (LICH), acute ischemic stroke (AIS),
cerebral microbleeding (CMB), or cortical superficial hemosiderosis (cSS):
Primary manifestation of CAA split by sex. The most common primary
manifestation was ICB in both male and female patients. No significant
differences could be found between the two sexes regarding primary
manifestation (chi-square: p > 0.63). One male patient had both ICB and
SAB/cSS and was counted to the ICB subgroup. The absolute numbers of
patients are given above the bars. Percentages refer to the subgroup (all male
patients, n = 105 and all female patients, n = 104).
data on smoking, therefore we did not include that factor in
our study.
Neurosonographic examination was available in 103 cases,
TTE in 58 patients, and cMRI in 133 patients.
Regarding the primary manifestation of CAA, there were
no significant differences based on sex (chi-square: p > 0.63).
LICH was by far the most common primary manifestation
(Figure 2) with a slight, non-significant higher percentage in
women compared to men (p > 0.23 in chi-square).
Arterial hypertension as a comorbidity was extremely frequent
in the patient with the CAA cohort. Only 15 of 190 patients
did not fulfill the predefined criteria for the diagnosis of AHT
at initial presentation resulting in a percentage of over 92%. No
therapy with antihypertensive drugs was present in about 25% of
patients with AHT at initial presentation (45/175).
With respect to the blood pressure at the initial presentation,
no significant differences were found between the subgroups
(ANOVA: p > 0.92). About one-third of the patients (58/164)
with AHT showed hypertensive crisis (systolic blood pressure ≥
180 mmHg) at initial presentation with a non-significant trend
(chi-square: p > 0.83) toward more frequent hypertensive crises
in the CMB (5/12 patients) and cSAH (5/11 patients) subgroups
compared to LICH (38/113 patients) and AIS (10/28). In the
overall cohort, 64/195 patients presented with hypertensive crisis.
Atrial fibrillation was frequent comorbidity with a lower
incidence of 14.8% (21/142) in the neurological and a higher
incidence of 28.8% (17/59) in the neurosurgical treated patients
(chi-square contingency: p< 0.035). There were large differences
betweenmen (25.3%= 25/99 AFib) and women (12.7%= 13/102
AFib), with men being affected more frequently by AFib than
women (p< 0.038 in chi-square). The incidence of AFib diverged
largely between the subgroups: 21.4% of patients (31/145) with
initial CAAmanifestation with LICH, 25.0% of the cSS-subgroup
(3/12), 10.3% of the AIS-subgroup (3/29), and 6.7% of the CMB-
subgroup had AFib (1/15). The highest incidence of AFib of
30.3% was observed in men with ICH as a primary manifestation
(20/66) (Figure 3).
Risk Factor Hypercholesterinemia/Statin
Therapy and CAA Subtypes
About one-third of patients (59/176) were treated with lipid-
lowering therapy (i.e., statin or fibrate) at hospital admission,
whereas only 39.6% (19/48) of the non-treated patients had a
low-density-lipoprotein <110 mg/dl. Due to the retrospective
study design and the small number of patients in the subgroups-
only 59 patients of the whole collective took statins or another
lipid-lowering medication, we decided not to perform subgroup
analysis here.
Risk Factor DM and Renal Insufficiency
and CAA Subtypes: No Significant
Influence of AHT on CAA Subtypes
38.4% (73/190) of patients suffered from renal insufficiency,
defined as GFR (according to Cockroft-Gault) below 60 ml/min
or intake of diuretics, and 20.5% (41/200) suffered from DM.
53.7% of patients with the diagnosis of DM (22/41) had IDM
diabetes. Albuminuria was present in 33.0% (32/97 patients).
Indications for Classical Cardiovascular
Risk Factors by Technical Examinations-
Neurosonographic Examination, TTE and
Fazekas-Score in MRI
According to neurosonographic examination (104/209 patients),
about one-fifth of patients (21/101) showed stenosis due
to NASCET-criteria. Echogenicity was heterogeneous, with
anechoic plaques (level 1–2) slightly more frequent (50/95) than
echogenic plaques (level 3–4) (45/95) (Figure 4). In TTE, 61%
(36/58) of patients had LVH or diastolic dysfunction. 39.4% of
patients had a positive anamnesis of cardiological comorbidities
(80/203). In 133 of 209 patients, MRI data were available.
For 74/209 patients, clinical routine follow-up was available
(Table 1). As a SVD marker, the Fazekas score was graded
for periventricular white matter lesions (PWML-133 pat.) and
deep white matter lesions (DWL-132 pat.) (Figure 5). For all
subgroups, a Fazekas score of 0 was less common than a score
of 1–3 without large differences between the subgroups.
High Percentage of Positive Classical
Cardiovascular Risk Factors in CAA
patients
On average, a patient showed 3.10/7 possible risk factors. The
highest percentage of present risk factors was shown in the
CMB group, with only slight differences between the different
subgroups (average number of positive risk factors: ICH-group:
3.14/7; AIS-group: 2.75/7; CMB-group 3.36/7; cSAH-group:
3.25/7) (Figure 6).
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FIGURE 3 | Incidence of atrial fibrillation (AFib) in neurological vs. neurosurgical treated patients and men vs. women by index event.
FIGURE 4 | Echogenity of plaques in neurosonographic examination.
DISCUSSION
There are large differences between the subgroups of CAA with
a different initial presentation, which is well in accordance with
previous studies (23–25). Primary ICH, in general, is more
frequent in men (23, 26, 27). Patients with cSS are known
to be an extremely vulnerable subgroup of patients with CAA
with a high probability of recurrent ICH (28, 29). As almost
50% of those patients present with the hypertensive crisis in
the emergency department, blood pressure management in this
subgroup is a significant problem. The question arises whether
the high number of hypertensive crises is a possible reason for
symptomatic cSS or whether cSS is the reason for dysregulated
high blood pressure.
The percentage of AHT at first presentation of CAA is far
higher than the average frequency of about 46% in the overall
adult population (30). Nevertheless, this high percentage might
also be due to the older age within the CAA cohort compared
to average adult age and, thus, cannot be compared directly with
this population.
Patients show high potential for primary prevention by
optimization of blood pressure management, e.g., by the general
practitioners. Moreover, optimal blood pressure control is also
a very important tool in secondary prophylaxis as good blood
pressure management is known to be associated with less
recurrent ICH, especially in patients with CAA (31, 32). Similar
results are shown for the treatment of hypercholesterinemia,
which was missing in about 60% of patients. This is higher than
that to be expected compared with the general prevalence of
elevated total cholesterol for a normal collective, which according
to the WHO for the Region of Europe is 54% for both sexes1
In this research, the primary preventive potential is again high
since patients not treated with lipid-lowering medication only
reach a favorable LDL level of <110 mg/dl in 35% of cases. The
incidence of DM (20%) at first sight is comparable with an age-
matched normal collective2 However, the high discrepancy in the
percentage of insulin-dependence in DM II between the literature
(26%) (33) and our collective (50%) suggests a high number of
unrecorded cases of NIDM, and therefore, a higher cumulative
incidence of DM in our collective than in an age-matched normal
collective. While the overall prevalence of chronic kidney disease
in patients older than 20 years is 15% (30), in our older patient
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TABLE 1 | Patient characteristics.
Department Neuro-logic: 149 Neuro-surgical:
60
Sex Female: 104 Male: 105
Age (years) MW: 72.32 STABWN: 8.06
Primary manifestation ICH: 151 AIS: 29 CMB: 16 cSAH/cSS: 13
Yes No Unknown
Hypertension 175 15 19
Hypertensive crisis 64 131 14
Lipid-lowering therapy 59 117 33
Hypercholesterinemia 80 29 100
Diuretics 65 112 32
Albuminuria 32 65 112
Vascular comorbidity 80 123 6
Atrial fibrillation 38 163 8
MRI 133 76 0
Follow-up (available only for patients of neurologic
Department)
75 74 0





GFR (ml/min; <60, >60, u = unknown) <60: 14 >60: 81 u: 114
Total number: 209; y, yes; n, no; u, unknown.
FIGURE 5 | Distribution of Fazekas scores among patients with CAA with
MRI. Overall, a Fazekas score of 0 was less common than scores of 1–3 for
both periventricular white matter lesions (PWML) and deep white matter
lesions (DWL).
most likely is explained by age; and more prevalent diabetes
and hypertension.
The high number of either pathologic findings in
neurosonographic examination or TTE, the high Fazekas scores
on MRI, and the high number of anamnestic cardiovascular
FIGURE 6 | Percentage of positive risk factors per subgroup.
comorbidities underpin the multimorbidity of the patient
collective. The highest number of risk factors were found in the
CMB-group, with 3.36/7 possible groups of risk factors positive
vs. the other subgroups, with 3.10/7 possible groups of risk
factors positive. This observation, together with our results of
another study which showed that patients of that subgroup suffer
the highest percentage of recurrent events in AIS (24), underlines
that the CMB group, which is at first sight supposed to be mildly
affected compared with patients presenting with a LICH, maybe
the most vulnerable group of the collective. Indeed, patients
with CMB may develop some type of protective mechanism
like shifting of essential functions from the regions prone to
bleed, which may also prevent further bleedings due to ongoing
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neuroplasticity, similar to patients with hemodynamically
relevant stenosis of a cerebral vessel who suffer an AIS in the
same region of the brain and are in part protected by ongoing
collateral vessel formation (34). Due to the retrospective study
design, in which patients with a second event were more likely
to get a follow-up if CMB protects against a further ICH, the
patients are more likely to get follow-up because of AIS. Yet, at
the same time, the CMB group may harbor a high primary and
secondary preventive potential.
The high number of concomitant cardiovascular risk factors
fit the high Fazekas score as a marker for microvascular lesions.
On the other hand, an interaction between WMH and CAA
was already shown by the fact that patients with more WMH
had a higher intensity of PiB (Pittsburgh compound B), showing
amyloid β (35).
Excluding hypertension, the prevalence of chronic vascular
disease (i.e., chronic heart disease, heart failure, and stroke)
is 9.0% overall. A positive history of myocardial infarction
was reported in 4.4% of patients, angina or chronic heart
disease in 4.1%, and heart failure in 2.2% (30) of patients. In
this research, the collective also shows a significantly higher
prevalence as 39.4% of the patients had a positive history of
cardiological comorbidities.
The large differences in the incidence of AFib between patients
in the Neurological vs. Neurosurgical Department might be
explained by the fact that patients with a large ICH or from
a smaller clinic are more likely treated in the neurosurgery
department, as the clinic as a tertiary referral center often gets
patients transferred from smaller hospitals. Therefore, there
might be a selection bias for worse cases toward the neurosurgery
department. This observation is in line with a large study on
ICH showing that patients with AFib-ICH were older and had
more vascular risk factors, more antithrombotic pretreatment, a
higher clinical severity, a higher hematoma volume, and higher
in-hospital and 3-month mortality (36). The higher incidence of
AFib in men is known from previous studies (37). We already
proved AFib to be frequent in a cohort of patients with CAA
treated in a neurosurgical ward (25.7%) with large differences
between patients with probable CAA (4%), probable CAA with
supporting pathology (33%), and possible CAA (38%) (25). In
a neurological ward setting, the incidence of AFib (16%) is
similar or only slightly higher than the cumulative incidence
of AFib in other age-matched collectives (10–16%) (41, 42).
AFib was shown to be reliable in predicting poor outcomes in
primary ICH (38, 39). The higher cumulative incidence of AFib
in neurosurgical treated patients with acute ICH may indicate
a deeper relationship with CAA in the sympathetic brain-heart-
axis, as already proposed by basic research (40).
STRENGTHS AND LIMITATIONS
Due to retrospective study design, especially for patients with
large LICH and primary palliative care concepts, datasets in some
cases are incomplete. For example, in 15 patients, data with the
information whether or not the patient is suffering from AHT
is lacking. Especially in patients with a primary poor prognosis
and palliative procedure, often, only basic data are available. The
information on IDM might also be biased, as it is more likely
to be recorded in patients with less information than those with
information on oral medication.
A strength of this study is that we included and compared
patients of neurological as well as neurosurgical ward and
therefore have less selection bias, supposing that patients with
larger bleedings are more often treated in the neurosurgical ward
and vice versa.
SUMMARY
Cerebral amyloid angiopathy as an important cause of LICH
is attracting increasing attention. Its frequency is increasing
with an aging population. Overlap of CAA and classical
cardiovascular comorbidities is high. While the prevalence of
AFib with 16% is only slightly higher than that in an age-
matched normal collective, AHT is extremely frequent with
a prevalence >90%. There are large differences in the risk
factors between the subgroups with different initial clinical
presentations and clinical follow-ups also. The high number of
concomitant cerebrovascular risk factors in patients with CAA,
and the fact that there are large differences for these between the
subgroups with a different initial presentation of CAA, makes
it highly probable that the risk factors are not only bystanders
but also modifiers. These data should be verified in a larger
patient collective.
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